Adjuvant Hypofractionated Radiotherapy for Prostate Cancer - Trial NCT06335693
Access comprehensive clinical trial information for NCT06335693 through Pure Global AI's free database. This phase not specified trial is sponsored by Changhai Hospital and is currently Recruiting. The study focuses on Prostate Cancer. Target enrollment is 9 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Changhai Hospital
Timeline & Enrollment
N/A
Mar 28, 2024
Feb 28, 2027
Primary Outcome
Incidence of radiotherapy-related gastrointestinal and genitourinary adverse events
Summary
Hypofractionated radiation therapy is a new type of radiotherapy which has been shown to play
 a larger role in the treatment of prostate cancer. The aims of the trial were to evaluate the
 safety and feasibility of adjuvant hypofractionated radiotherapy following radical
 prostatectomy for prostate cancer.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06335693
Non-Device Trial